SUSTAINED IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING REPEAT ONABOTULINUMTOXINA DETRUSOR INJECTIONS IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY: RESULTS FROM TWO PHASE 3 STUDIES

被引:0
|
作者
Chartier-Kastler, E. [1 ]
Rovner, E. [2 ]
Chancellor, M. [3 ]
Corbell, C. [4 ]
Jin, J. [4 ]
Globe, D. [4 ]
机构
[1] Univ Paris 06, Dept Urol, Paris, France
[2] Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA
[3] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA
[4] Allergan Pharmaceut Inc, Irvine, CA USA
关键词
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
174
引用
收藏
页码:763 / 764
页数:2
相关论文
共 50 条
  • [22] Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity
    Reitz, Andre
    Denys, Pierre
    Fermanian, Christophe
    Schurch, Brigitte
    Comperat, Eva
    Chartier-Kastler, Emmanuel
    EUROPEAN UROLOGY, 2007, 52 (06) : 1729 - 1735
  • [23] Sustained improvement in urinary incontinence and quality of life with onabotulinumtoxin A regardless of baseline EDSS score in MS patients with neurogenic detrusor overactivity
    Tullman, M.
    Denys, P.
    Jenkins, B.
    Joshi, A. J.
    Zhou, J.
    Yushmanova, I.
    Fowler, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 100 - 100
  • [24] What aspects of quality of life are improved following intra-detrusor injections of botulinum toxin-A in patients with overactive bladder and idiopathic detrusor overactivity.
    Sahai, A.
    Khan, M. S.
    Dasgupta, P.
    JOURNAL OF ENDOUROLOGY, 2006, 20 : A59 - A59
  • [25] REPEAT ONABOTULINUMTOXINA TREATMENT IN SPINAL CORD INJURY PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY: FINAL ANALYSIS OF 4 YEARS' FOLLOW-UP CONFIRMS SUSTAINED SAFETY AND EFFICACY
    Kennelly, M.
    Schulte-Baukloh, H.
    Dmochowski, R.
    Ethans, K.
    Moore, C.
    Zheng, Y.
    Guard, S.
    Jenkins, B.
    Karsenty, G.
    NEUROUROLOGY AND URODYNAMICS, 2014, 33 (06) : 833 - 834
  • [26] Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
    Navarro Compan, Victoria
    Dubreuil, Maureen
    Gaffney, Karl
    Kay, Jonathan
    de la Loge, Christine
    Massow, Ute
    Taieb, Vanessa
    Vaux, Thomas
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3015 - 3018
  • [27] Efficacy and Safety of OnabotulinumtoxinA Therapy are Sustained Over 4 Years of Treatment in Patients With Neurogenic Detrusor Overactivity: Final Results of a Long-Term Extension Study
    Kennelly, Michael
    Dmochowski, Roger
    Schulte-Baukloh, Heinrich
    Ethans, Karen
    Del Popolo, Giulio
    Moore, Courtenay
    Jenkins, Brenda
    Guard, Steven
    Zheng, Yan
    Karsenty, Gilles
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 (02) : 368 - 375
  • [28] Improvements in health-related quality of life and symptoms of depression with tofacitinib: Results from two randomized phase 3 studies in patients with moderate to severe psoriasis
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Bundy, Christine
    Korman, Neil J.
    Lan, Shuping
    Robertson, Deborah
    Tatulych, Svitlana
    Tallman, Anna
    Kaur, Mandeep
    Mamolo, Carla
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [29] Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review
    Tapia, Crisanta I.
    Khalaf, Kristin
    Berenson, Karina
    Globe, Denise
    Chancellor, Michael
    Carr, Lesley K.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
  • [30] Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review
    Crisanta I Tapia
    Kristin Khalaf
    Karina Berenson
    Denise Globe
    Michael Chancellor
    Lesley K Carr
    Health and Quality of Life Outcomes, 11